InvestorsHub Logo
Followers 56
Posts 1684
Boards Moderated 0
Alias Born 04/22/2022

Re: HyGro post# 516324

Friday, 09/23/2022 12:54:21 PM

Friday, September 23, 2022 12:54:21 PM

Post# of 716042
That’s actually a wise statement, HyGro. You have been listening to me after all. You are correct—the forthcoming peer review will be a reliable source.

So, you do believe in the great value of peer review. That makes sense.

Dr. Liau has authored over 170 peer-reviewed research articles, along with several book chapters, and a textbook entitled Brain Tumor Immunotherapy. She is on the editorial boards of several scientific/medical journals and was the Editor-in-Chief of the Journal of Neuro-Oncology (2007–2017).

"Peer review has been the foundation of scholarly publishing and scientific communication since the 1665 publication of the Philosophical Transactions of the Royal Society. The benefits and advantages of peer review in scientific research, and particularly medical research, are manifold and manifest."

Dr. Liau will be presenting DCVax at the annual Society for Neuro-Oncology meeting in November.

“The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.”

“The annual SNO meeting is the academic and educational nexus for the latest findings from all neuro-oncology subspecialties and disciplines.”

Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial

Plenary Abstract Presenter: Linda M. M. Liau, MD PhD
- University of California, Los Angeles

https://www.uclahealth.org/providers/linda-liau

https://soc-neuro-onc.org/

https://doi.org/10.3171/2020.12.FOCUS20954

https://virtualtrials.org/dcvax.cfm
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News